Researchers appear to be nearing a significant advancement in the treatment of cystic fibrosis. The Cystic Fibrosis Foundation has collaborated with the biotech firm Antiverse to leverage cutting-edge artificial intelligence to create antibodies that specifically target the CFTR protein — the primary protein impacted in cystic fibrosis.
For many years, identifying antibodies that can engage with membrane proteins like CFTR has proven to be exceedingly challenging. Conventional techniques may require one to two years and frequently do not succeed. Antiverse is confident that its generative AI platform can significantly shorten this timeframe by developing therapeutic antibodies in under four months.
By utilizing AI modeling alongside rapid laboratory testing, the company can swiftly create, evaluate, and refine antibodies aimed at the extracellular domains of intricate proteins. These antibodies undergo initial screening in specialized cell lines, followed by testing in native cell models facilitated by the Cystic Fibrosis Foundation.
In addition to this collaboration, Antiverse has successfully secured $9.3 million in new funding to enhance its pipeline. The company is directing its efforts towards diseases where conventional antibody discovery has faced challenges, such as metabolic disorders, lung ailments, and complex receptor targets.
If this AI-enhanced platform proves effective, it could pave the way for new therapies for conditions that have long eluded scientific treatment.
